UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

Annals of oncology, 2019-11, Vol.30 (11), p.1776-1783

2019

Volltextzugriff (PDF)

Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy

Annals of oncology, 2012-08, Vol.23 (8), p.2046-2052

2012

Volltextzugriff (PDF)

HoxA9-mediated immortalization of myeloid progenitors requires functional interactions with TALE cofactors Pbx and Meis

Oncogene, 2000-02, Vol.19 (5), p.608-616

2000

Volltextzugriff (PDF)

Trimeric Association of Hox and TALE Homeodomain Proteins Mediates Hoxb2 Hindbrain Enhancer Activity

Molecular and Cellular Biology, 1999-07, Vol.19 (7), p.5134-5142

1999

Volltextzugriff (PDF)

CREB Binding Protein Interacts with Nucleoporin-Specific FG Repeats That Activate Transcription and Mediate NUP98-HOXA9 Oncogenicity

Molecular and Cellular Biology, 1999-01, Vol.19 (1), p.764-776

1999

Volltextzugriff (PDF)

Repression by HoxA7 is mediated by the homeodomain and the modulatory action of its N-terminal-arm residues

Molecular and Cellular Biology, 1996-06, Vol.16 (6), p.2678-2688

1996

Volltextzugriff (PDF)

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

Clinical cancer research, 2013-08, Vol.19 (15), p.4196-4205

2013

Volltextzugriff (PDF)

A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

Annals of oncology, 2019-10, Vol.30 (5), p.v851

2019

Volltextzugriff (PDF)

Abstract P5-04-22: Withdrawn

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-04-22

2019

Volltextzugriff (PDF)

LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Abstract P1-06-09: Correlation of breast cancer index (BCI) results to lymphovascular invasion in early stage HR+ breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-06-09

2018

Volltextzugriff (PDF)

Abstract P1-07-18: Clinicopathologic and molecular correlates of breast cancer index (BCI) results in patients with HR+, LN- breast cancer that are high risk of late distant recurrence (DR) / low likelihood of benefit from extended endocrine therapy (EET)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-07-18

2018

Volltextzugriff (PDF)

Abstract P4-09-09: Correlation of breast cancer index (BCI) predictive (HoxB13/IL17BR) results to nodal status and hormone receptor expression in early stage HR+ breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-09-09

2018

Volltextzugriff (PDF)

Abstract P1-07-12: Correlation of breast cancer index (BCI) prognostic and predictive results to clinicopathologic risk groups in early stage HR+ breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-07-12

2018

Volltextzugriff (PDF)

Abstract P2-05-18: Correlation of breast cancer index (BCI) risk classification with tumor grade and Ki-67 in a large series of patients with early-stage, ER+ breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-05-18

2017

Volltextzugriff (PDF)

Abstract P2-08-42: Use of breast cancer index to analyze tumor proliferation and endocrine responsiveness in genomic intermediate risk patients

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-08-42

2019

Volltextzugriff (PDF)

Abstract P2-05-14: Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, T1 breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-05-14

2017

Volltextzugriff (PDF)

Abstract P2-08-12: Integration of tumor size and grade with the breast cancer index (BCI) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-08-12

2016

Volltextzugriff (PDF)

Abstract P5-03-01: An optimized 92-gene assay for the molecular diagnosis of triple-negative breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-03-01

2017

Volltextzugriff (PDF)

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial

Annals of oncology, 2019-11, Vol.30 (11), p.1776

2019

Volltextzugriff (PDF)

Abstract P1-06-10: Correlative analysis of breast cancer index (BCI) restratification of 21-gene recurrence score (RS) in patients with hormone receptor-positive (HR+), node-negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-06-10

2018

Volltextzugriff (PDF)

Abstract P6-09-03: Gene expression patterns in younger versus older HR+ breast cancer patients: An age-related analysis of HoxB13/IL17BR (H/I), proliferation status, and quantitative hormone receptor expression

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-09-03

2018

Volltextzugriff (PDF)

Pbx1 is essential for adrenal development and urogenital differentiation

Genesis (New York, N.Y. : 2000), 2003-11, Vol.37 (3), p.123-130

2003

Volltextzugriff (PDF)

Abstract P5-08-03: Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-08-03

2016

Volltextzugriff (PDF)

Abstract P2-05-08: Impact of treatment history on prognostic ability of breast cancer index (BCI): Subset analysis from a validation study of patients with hormone receptor-positive (HR+) breast cancer with 1-3 positive nodes

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-05-08

2017

Volltextzugriff (PDF)

1 – 25 von 1.957

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.742)
Mit Volltextzugriff
(1.722)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.827)
Deutsch
(103)
Französisch
(34)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.243)
Life Sciences & Biomedicine
(625)
Technology
(502)
Humans
(451)
Computer Science
(421)
Computer Science, Theory & Methods
(389)
Female
(302)
Imaging Science & Photographic Technology
(283)
Male
(259)
Physical Sciences
(206)
Biological And Medical Sciences
(194)
Middle Aged
(189)
Animals
(159)
Medical Sciences
(159)
Adult
(154)
Aged
(154)
Physics
(131)
Cardiovascular System & Cardiology
(85)
Oncology
(84)
Cardiac & Cardiovascular Systems
(77)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy

HoxA9-mediated immortalization of myeloid progenitors requires functional interactions with TALE cofactors Pbx and Meis

Trimeric Association of Hox and TALE Homeodomain Proteins Mediates Hoxb2 Hindbrain Enhancer Activity

CREB Binding Protein Interacts with Nucleoporin-Specific FG Repeats That Activate Transcription and Mediate NUP98-HOXA9 Oncogenicity

Repression by HoxA7 is mediated by the homeodomain and the modulatory action of its N-terminal-arm residues

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

Abstract P5-04-22: Withdrawn

LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

Abstract P1-06-09: Correlation of breast cancer index (BCI) results to lymphovascular invasion in early stage HR+ breast cancer

Abstract P1-07-18: Clinicopathologic and molecular correlates of breast cancer index (BCI) results in patients with HR+, LN- breast cancer that are high risk of late distant recurrence (DR) / low likelihood of benefit from extended endocrine therapy (EET)

Abstract P4-09-09: Correlation of breast cancer index (BCI) predictive (HoxB13/IL17BR) results to nodal status and hormone receptor expression in early stage HR+ breast cancer

Abstract P1-07-12: Correlation of breast cancer index (BCI) prognostic and predictive results to clinicopathologic risk groups in early stage HR+ breast cancer

Abstract P2-05-18: Correlation of breast cancer index (BCI) risk classification with tumor grade and Ki-67 in a large series of patients with early-stage, ER+ breast cancer

Abstract P2-08-42: Use of breast cancer index to analyze tumor proliferation and endocrine responsiveness in genomic intermediate risk patients

Abstract P2-05-14: Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, T1 breast cancer

Abstract P2-08-12: Integration of tumor size and grade with the breast cancer index (BCI) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes

Abstract P5-03-01: An optimized 92-gene assay for the molecular diagnosis of triple-negative breast cancer

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial

Abstract P1-06-10: Correlative analysis of breast cancer index (BCI) restratification of 21-gene recurrence score (RS) in patients with hormone receptor-positive (HR+), node-negative breast cancer

Abstract P6-09-03: Gene expression patterns in younger versus older HR+ breast cancer patients: An age-related analysis of HoxB13/IL17BR (H/I), proliferation status, and quantitative hormone receptor expression

Pbx1 is essential for adrenal development and urogenital differentiation

Abstract P5-08-03: Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study

Abstract P2-05-08: Impact of treatment history on prognostic ability of breast cancer index (BCI): Subset analysis from a validation study of patients with hormone receptor-positive (HR+) breast cancer with 1-3 positive nodes

Suchergebnisse filtern